本文選題：鼻咽癌 + 抗體��； 參考：《現(xiàn)代腫瘤醫(yī)學(xué)》2016年19期

【摘要】：目的:評(píng)價(jià)EB病毒(EBV)抗衣殼抗原VCA-IgA抗體、抗早期抗原EA-IgA抗體、抗立即早期抗原Rta-IgG抗體和EBV-DNA檢測(cè)在鼻咽癌診斷中的價(jià)值。方法:收集160例初治鼻咽癌,133例癥狀相似的非鼻咽癌患者和163名健康體檢者的血清和血漿。采用酶聯(lián)免疫法檢測(cè)血清VCA-IgA、EA-IgA和RtaIgG抗體的水平,用實(shí)時(shí)熒光定量PCR檢測(cè)血漿EBV-DNA的相對(duì)含量。按鼻咽癌2008臨床TNM分期法進(jìn)行分期,計(jì)算不同分組、各臨床分期以及鼻咽癌治療前后的各抗體陽(yáng)性率、抗體水平以及EB-DNA的檢測(cè)結(jié)果并進(jìn)行數(shù)據(jù)分析。結(jié)果:鼻咽癌組VCA-IgA、EA-IgA、Rta-IgG和EBV-DNA陽(yáng)性率均高于鼻咽相關(guān)疾病組及健康對(duì)照組(均P0.05)。血清VCA-IgA和EA-IgA結(jié)果相對(duì)A值(即r A或S/CO值)在Ⅰ、Ⅱ期低于Ⅲ、Ⅳ期,差異有統(tǒng)計(jì)學(xué)意義(P0.05),但陽(yáng)性率在各期間比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05);Ⅰ、Ⅱ期患者Rta-IgG的r A值和陽(yáng)性率明顯低于Ⅲ、Ⅳ期患者(P0.05);血漿中EBV-DNA陽(yáng)性率及EBVDNA中位數(shù)水平隨著臨床分期的升高而增高,Ⅰ、Ⅱ期與Ⅲ、Ⅳ期比較差異有統(tǒng)計(jì)學(xué)意義(P0.05)。治療有效(CR+PR)患者的EBV-DNA含量明顯低于治療前水平(P0.05)。結(jié)論:VCA-IgA、EA-IgA、RtaIgG、EBV-DNA檢測(cè)有助于鼻咽癌的輔助診斷、臨床分期預(yù)測(cè)及療效評(píng)估。
[Abstract]:Objective: to evaluate the value of Epstein-Barr virus (EBV) anti-capsid antigen VCA-IgA antibody, anti-early antigen EA-IgA antibody, anti-immediate early antigen Rta-IgG antibody and EBV-DNA detection in the diagnosis of nasopharyngeal carcinoma. Methods: the serum and plasma of 160 patients with nasopharyngeal carcinoma (NPC) with similar symptoms, 133 patients with non nasopharyngeal carcinoma (NNPC) and 163 healthy controls were collected. The levels of serum VCA-IgAEA-IgA and RtaIgG antibodies were detected by enzyme-linked immunosorbent assay (Elisa), and the relative content of plasma EBV-DNA was detected by real-time fluorescence quantitative PCR. According to the clinical TNM staging method of nasopharyngeal carcinoma (NPC) 2008, the positive rate of antibody, the level of antibody and the detection results of EB-DNA were calculated and analyzed in different groups, clinical stages and before and after treatment of nasopharyngeal carcinoma. Results: the positive rates of VCA-IgAEA-IgAEA-IgAEA-Rta-IgG and EBV-DNA in nasopharyngeal carcinoma group were higher than those in nasopharyngeal related disease group and healthy control group (all P 0.05). The relative A value of serum VCA-IgA and EA-IgA (i.e. r A or S/CO) in stage 鈪，

本文編號(hào)：1819561